Introduction
cancer
CANCER
The enzyme cluster of differentiation 73 (CD73) is an important component of the regulatory signaling network mediating immune activation and suppression in the cellular microenvironment [Immunotherapy is transforming cancer treatment, but durable response is seen in a limited proportion of patients as primary or acquired resistance to treatment represents a major challenge [Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody that potently and selectively inhibits the catalytic activity of CD73 via steric blocking and inter-CD73 dimer crosslinking, and decreases CD73 expression through internalization, thereby inhibiting the production of immunosuppressive extracellular adenosine [